UBS Group
ANGO icon

UBS Group’s AngioDynamics ANGO Stock Holding History

UBS Group’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200
Closed -$4K – 8762
2014
Q4 		$4K Buy
+200
New +$3.39K ﹤0.01% 9086

Other funds holding ANGO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $5.02B AUM 66.06% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
BH
Broadfin Holdings Melville, New York $23.7M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WCM
Weber Capital Management San Francisco, California $118M AUM
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's ANGO Position: Q2 2026 in Review

UBS Group reduced its AngioDynamics (ANGO) stake by 78% in Q2 2026, selling an estimated $3.5M and leaving 84,187 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #5652.

UBS Group first reported a position in ANGO in Q4 2014 and has held it in 47 quarters since. The position peaked at $12.3M in Q3 2025. 162 funds tracked by Wall St. Rank hold ANGO as of Q2 2026.

  • UBS Group held 84,187 shares of AngioDynamics worth $1.1M as of Q2 2026.
  • UBS Group sold 307,098 AngioDynamics shares in Q2 2026, an estimated $3.5M.
  • AngioDynamics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5652 holding.
  • UBS Group first reported a position in AngioDynamics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's AngioDynamics position peaked at $12.3M in Q3 2025.
  • 162 funds tracked by Wall St. Rank held AngioDynamics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.